Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agenus Inc AGEN

Healthcare Biotechnology
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its... see more

Recent & Breaking News (NDAQ:AGEN)

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 8 days ago

Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting

Business Wire 9 days ago

Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

Business Wire 10 days ago

FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer

Business Wire May 16, 2024

Agenus Reports First Quarter 2024 Results

Business Wire May 7, 2024

Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement

Business Wire May 7, 2024

Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement

Business Wire May 1, 2024

Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting

Business Wire April 24, 2024

Agenus to Provide First Quarter 2024 Financial Report and Corporate Update

Business Wire April 23, 2024

Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer

Business Wire April 12, 2024

Agenus Announces Reverse Stock Split of Common Stock

Business Wire April 5, 2024

Agenus Reports Fourth Quarter and Full Year 2023 Results

Business Wire March 14, 2024

Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024

Business Wire March 6, 2024

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 5, 2024

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Business Wire February 29, 2024

Agenus to Participate in Leerink Partners Global Biopharma Conference

Business Wire February 26, 2024

Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design

PR Newswire February 15, 2024

Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference

Business Wire January 31, 2024

Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population

Business Wire January 22, 2024

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire January 5, 2024